NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

RecruitingPhase 4

Sponsor: Samsung Medical Center

Conditions: Atrial Fibrillation, SGLT2 Inhibitor, DC Cardioversion

Interventions: SGLT2 inhibitors (Dapagliflozin and Empagliflozin)

Countries: South Korea

SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.

Eligibility overview

Sex: ALL

Age: 19 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥19 years
* Persistent atrial fibrillation
* H2FPEF score ≥6 or HFA-PEFF score ≥5
* Restoration of sinus rhythm after electrical cardioversion

Exclusion Criteria:

* Previous use of an SGLT2 inhibitor
* Intracardiac thrombus on transesophageal echocardiography
* Refusal to participate

Locations (1)

Seoul, Seoul, South Korea